- CDIB Capital Management - CDIB Capital Healthcare Ventures Limited- CDIB Capital Healthcare Ventures II L.P.- Healthcare fund investments and manage: Leading innovative biotechnologies- Participate in CDIB health care funds raising- Projects reviewer in academia & government- Mentor in startup programs & accelerators

- IVD business (TBG Biotechnology Corp) Spin-off from Medigen- Strategic business planning/ Project evaluation/ Due diligence- Resource integration/commercialization/market analysis/business alliance & collaboration- Connect/utilize different capabilities and resources- IRB planning/execution with clinical evaluations - Executive secretary in Taiwan Molecular diagnosis Alliance (台灣生醫分子檢測產業聯盟)

- Principle investigator in Strategic Business & Innovation Technology Development Division. - Principle Investigator in Drug/ cell application/ medical device associated projects- Innovative, translatable researches exhibited from bench to clinics - Task force team buildup (8 members) for drug/cell application/medical device development: Molecular targeting/Drug screening/ Cancer stem cells /Signal transduction/ Tyrosine kinases/ PD-PK correlation/ novel cell applications- Well-established partnership with KOLs and clinicians in both academia and industries- Construct/connect the industry R&D value chain capability, including platform and core service facilities- Drug discovery, development and technology transfer: ITRI-260, a new drug for AML treatment (to Anchen Biopharm 安成- RuenHuei Biopharm潤惠)- Medical device development and technology transfer (pre-participation): Automatic processing device for adipose tissue-derived stem cell (Gemmy industrial Corp. 璟明實業)- Cell Line establishment: 2 novel, unique HCV-related hepatocellular carcinoma cell lines establishment- Invited speaker, 2012 International Symposium on Recent Advances in Stem Cells and Cancer & The 8th Annual Meeting of TSSCR: Cancer stem cell study in hepatocellular carcinoma

- Principle investigator in cell engineering lab. - Principle investigator in various Technology Development Programs, including small molecule drug development, herbal medicine development, medical device,regeneration medicine, stem cell technology and companion diagnostics. - Task force team buildup for oncology and translation projects, including molecular targeting, drug screening, cancer stem cells, signal transduction, tyrosine kinase/receptors, molecular markers for diagnosis and prognosis.

— Projects dual diligence: potential new drug/medical device projects evaluation for a clearer commercialization path— Establish drug development value chain for Liver cancer/Lung cancer: potential new drugs can employ this value chain to improve their commercialization success rate— Built up the connection between KOLs, clinicians, research/medical centers, infrastructures, National Science Council, and National Research Program for Biopharmaceuticals (NRPB).— Bridge up between academia and industry and promote to speed up in the commercialization process